行情

ACRX

ACRX

AcelRx制药
NASDAQ

实时行情|Nasdaq Last Sale

1.680
-0.060
-3.45%
盘后: 1.690 +0.01 +0.60% 17:10 11/15 EST
开盘
1.750
昨收
1.740
最高
1.750
最低
1.670
成交量
118.25万
成交额
--
52周最高
4.090
52周最低
1.670
市值
1.34亿
市盈率(TTM)
-2.5127
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACRX 新闻

  • 关厂风波肆起、显示屏遭质疑:三星能否靠5G绝地求生
  • 蓝鲸TMT.23分钟前
  • 约翰逊承诺结束令经济“陷入瘫痪”的英退不确定性
  • 新浪财经综合.33分钟前
  • 一周财经日历丨美团、拼多多财报出炉,阿里或于周三定价
  • 华盛通.38分钟前
  • 蔚来宣布奉玮出任CFO 后者曾任中金研究部董事总经理
  • 新浪科技.1小时前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

ACRX 简况

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
展开

Webull提供AcelRx Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。